References
- Andre FE, Booy R, Bock HL Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008 Feb;86(2):140–146.
- Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130433.
- Carroll S, Rojas AJ, Glenngard AH Vaccination: short- to long-term benefits from investment. J Mark Access Health Policy. 2015;3.
- Largeron N, Levy P, Wasem J Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy. 2015;3.
- Postma MJ, Carroll S, Brandao A. The societal role of lifelong vaccination. J Mark Access Health Policy. 2015;3.
- Quilici S, Smith R, Signorelli C. Role of vaccination in economic growth. J Mark Access Health Policy. 2015;3.
- Remy V, Zollner Y, Heckmann U. Vaccination: the cornerstone of an efficient healthcare system. J Mark Access Health Policy. 2015;3.
- Bonanni P, Picazo JJ, Remy V. The intangible benefits of vaccination - what is the true economic value of vaccination? J Mark Access Health Policy. 2015;3.
- World Health Organization. Guiding Principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond. 2022.
- European Commission. A European one health action plan against antimicrobial resistance (AMR). 2017.
- Zhou F, Shefer A, Wenger J Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics. 2014 Apr;133(4):577–585.
- Boccalini S, Taddei C, Ceccherini V Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother. 2013 May;9(5):1119–1128.
- Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006 Dec;26(6):1423–1440.
- Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine. 2002 Jun 7;20(19–20):2562–2578.
- Orenstein W, Offit P, Edwards KM Plotkin’s vaccines. 7th Edition ed.: Elsevier; 2017.
- Vaccination: Commission calls for stronger EU cooperation against preventable diseases [Internet]. 2018. Available from: https://ec.europa.eu/commission/presscorner/detail/en/IP_18_3457
- European Commission. Strengthened cooperation against vaccine preventable diseases. 2017.
- Courvoisier T, Charpentier B, van der Meer JWM Vaccination in Europe: an EASAC and FEAM commentary on the EC Roadmap ‘Strengthened cooperation against vaccine preventable diseases’
- The Lancet. Addressing decreasing vaccine coverage in the EU. Lancet. 2018 Apr 28;391(10131):1638.
- Republic of Bulgaria National Council on Prices and Reimbursement of Medicinal Products. Ordinance on the terms, rules and procedure for regulation and registration of prices for medicinal products 2021. Available from: https://ncpr.bg/en/regulations/bulgarian-legislation/regulations.html
- Organisation for economic co-operation and development. OECD.Stat. Available from: https://stats.oecd.org/Index.aspx?ThemeTreeId=9
- European Commission. Exchange rate (InforEuro). Available from: https://ec.europa.eu/info/funding-tenders/procedures-guidelines-tenders/information-contractors-and-beneficiaries/exchange-rate-inforeuro_en
- European Medicines Agency. Zostavax 2016. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zostavax
- Datapharm. VARIVAX 2022. Available from: https://www.medicines.org.uk/emc/product/5582/smpc
- European Medicines Agency. Use of Varilrix (live attenuated varicella virus [Oka strain]) to be harmonised in the EU 2021. Available from: https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonized_en.pdf
- European Medicines Agency. Menveo, INN-meningococcal Group A, C, W135 and Y conjugate vaccine. Available from: https://www.ema.europa.eu/en/documents/product-information/menveo-epar-product-information_en.pdf
- European Medicines Agency. Nimenrix 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nimenrix
- European Medicines Agency. Bexsero 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bexsero
- European Medicines Agency. Trumenba, INN-Meningococcal group B vaccine. Available from: https://www.ema.europa.eu/en/documents/product-information/trumenba-epar-product-information_en.pdf
- GlaxoSmithKline. Havrix junior vaccine 2020. Available from: https://gskpro.com/content/dam/global/hcpportal/en_CY/PDF/Homepage/Products/Havrix/smpc-havrix-720-junior-12-08-2020-en.pdf
- European Medicines Agency. HBVaxPro 2011. Available from: https://www.ema.europa.eu/en/documents/overview/hbvaxpro-epar-summary-public_en.pdf
- Ethgen O, Cornier M, Chriv E The cost of vaccination throughout life: a Western European overview. Hum Vaccin Immunother. 2016 Aug 2;12(8):2029–2037.
- Ethgen O, Remy V, Wargo K. Vaccination budget in Europe: an update. Hum Vaccin Immunother. 2018;14(12):2911–2915.
- Baron-Papillon F, Cornier M, Remy V What are the lifelong costs of vaccinating one individual? The French case. Value Health. 2014 Nov;17(7):A672.
- Soler Soneira M, Olmedo Lucerón C, Sánchez-Cambronero Cejudo L El coste de vacunar a lo largo de toda la vida en España. Rev Esp Salud Pública. 2020;94:e202002005.